Natera Inc (NTRA)

112.83 +1.74  +1.57% NASDAQ Feb 24, 20:00 USD
View Full Chart
Price Chart
View All NTRA News

News

View All Events

Events

Date Type Description
02/25/2021 Earnings Natera Inc Fourth Quarter Earnings Result for 2020
02/25/2021 16:30 EST Misc Natera Inc Fourth Quarter Earnings Conference Call for 2020
11/05/2020 Earnings Natera Inc Third Quarter Earnings Result for 2020
11/05/2020 16:30 EST Misc Natera Inc Third Quarter Earnings Conference Call for 2020
08/05/2020 16:30 EDT Misc Natera Inc Second Quarter Earnings Conference Call for 2020
08/05/2020 Earnings Natera Inc Second Quarter Earnings Result for 2020
05/28/2020 11:30 PDT Misc Natera Inc Annual General Meeting for 2019
05/06/2020 16:30 EDT Misc Natera Inc First Quarter Earnings Conference Call for 2020
05/06/2020 Earnings Natera Inc First Quarter Earnings Result for 2020
03/02/2020 Misc Natera Inc Annual Report for 2019
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.natera.com
  • Investor Relations URL: http://investor.natera.com/phoenix.zhtml?c=254055&p=irol-irhome
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Diagnostics & Research
  • Equity Style: Mid Cap/Growth
  • Next Earnings Release: Feb. 25, 2021
  • Last Earnings Release: Feb. 25, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Natera Inc is operative in the healthcare field in the United States. Its core business is to offer invasive and other means of diagnosing genetic features of a fetus. Natera's array of diagnostic services include Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Anora Products of Conception (POC) test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing (PAT), to determine paternity by studying the fragments of fetal deoxyribonucleic acid (DNA) in a pregnant mother's blood and a blood sample from the alleged father. The Company acquires its revenue by billing an insurance carrier, a clinic or a patient for the test upon delivery of the test result.

Top Fund Holders

Symbol Name Weighting
GNOM Global X Genomics & Biotechnology ETF 4.96%
AOFCX Alger Small Cap Focus C 4.79%
PJHRX PGIM Jennison Health Sciences R 3.41%
WGFCX Wells Fargo Growth C 2.16%
DCCRX Delaware Small Cap Core R 1.96%
JGLYX JPMorgan Small Cap Growth R4 1.72%
FKBSX Federated Hermes Kaufmann Small Cap B 1.03%
XBI SPDR® S&P Biotech ETF 0.97%
VTWG Vanguard Russell 2000 Growth ETF 0.56%
IWO iShares Russell 2000 Growth ETF 0.55%
VTWO Vanguard Russell 2000 ETF 0.30%
IWM iShares Russell 2000 ETF 0.30%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.